24 Feb 2023

SVT-15473 + IMPACT-SVT® Nanoemulsion technology

Salvat has developed IMPACT-SVT®, a patented nanoemulsion drug delivery technology that improves drug mucus penetration and bio-adhesion, providing excellent ocular comfort.

IMPACT-SVT® made it possible to develop SVT-15473, using the strongest corticosteroid in the global market.

Content provided by our supplier

Laboratorios Salvat, S.A.

  • ES
  • 2016
    On CPHI since
  • 4
  • 100 - 249
Company types
Contract Research Organisation (CRO)
Drug delivery device Supplier/Manufacturer
Pharmaceutical company
Primary activities
Contract Manufacturer
Contract Research Organisation
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)

Other Content from Laboratorios Salvat, S.A. (6)

  • News Salvat Laboratory Submits Application to the US FDA for Approval of Clotrimazole, a Pioneering Drug for the Treatment of Otomycosis

    • The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa.
    • Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international level. 


  • Brochure Cristalmina® - Topical antiseptic

    Cristalmina®, offers a quick action and long-lasting effect. 
    Indicated in the disinfection of burns and superficial wounds; even for the umbilical cord in newborns.

    Chlorhexidine is the antiseptic of reference, widely recommended in different clinical guidelines.

    Licensing opportunity: Cristalmina®, 10 mg/ml, cutaneous spray solution in 25 ml & 125 ml.
  • News Salvat Laboratories announces submission of New Drug Application to the US FDA for Clobetasol Nanoemulsion

    Salvat Laboratories, the international company, which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.
  • Brochure CDMO Services

    Salvat offers an integrated End-to-Endsolution, to ensure your project’s commercial success. We offer the latest technologies withoptimum quality, flexibility andoperational excellence. With over 65years of experience, we can provide theservices and solutions that make ourpartners successful.
  • Brochure Licensing product list

    Sharing a commitmentto patients worldwide

    LICENSING-OUT our products focuson Ophthalmology, Otorhinolaryngology,Gastroenterology & Consumer Health Care.

    LICENSING-IN products for the Spanish,Portuguese, African and Central Americamarkets. Our areas of interest are in Rx productsat Ophthalmology, Otorhinolaryngology andGastroenterology.
  • Video New manufacturing capabilities - Sterile liquids

    Over 60 years of experience in the pharmaceutical industry Salvat offers a complete CDMO services 
    Expertise in Blow-Fill-Seal technology 
    Manufacturing sites located at Barcelona, Madrid & Miami